CLAIMS

1. A pharmaceutical composition in the form of a soft capsule for oral administration comprising:

a. 1 to 35% (w/w) of fexofenadine hydrochloride ;

b. At least 60%(w/w) of a liquid mixture of at least one non-ionic hydrophilic surfactant and at least one non-ionic hydrophobic surfactant.

~~2. The pharmaceutical composition according to claim 1, wherein the fexofenadine hydrochloride has a specific surface area ranging from 1.0 and 4.0 m^2/g.~~

2~~3~~. The pharmaceutical composition according to claim 1, wherein the total amount of surfactant is ranging from 65 to 85% by weight of the composition.

3~~4~~. The pharmaceutical composition according to claim 1, wherein the non-ionic hydrophobic surfactant has an HLB value from 4 to 6.

4~~5~~. The pharmaceutical composition according to claim 1, wherein the non-ionic hydrophobic surfactant is chosen from the group consisting of propylene glycol laurate, propylene glycol monocaprylate and mixture thereof.

5~~6~~. The pharmaceutical composition according to claim 1, wherein the hydrophobic surfactant is present in amounts ranging from 75% to 80% by weight of the composition.

6~~7~~. The pharmaceutical composition according to claim 1, wherein the non-ionic hydrophilic surfactant has an HLB value from 11 to 16.

7~~8~~. The pharmaceutical composition according to claim 1, wherein the non-ionic hydrophilic surfactant is the polysorbate 80.

8~~9~~. The pharmaceutical composition according to claim 1, wherein the non-ionic hydrophilic surfactant is present in amounts ranging from 1% to 10% by weight of the composition.

9~~10~~. The pharmaceutical composition according to claim 1, wherein the weight ratio of fexofenadine hydrochloride to the total liquid mixture of surfactant is 1:4.

10~~11~~. The pharmaceutical composition according to claim 1, wherein the non-ionic hydrophobic surfactant is propylene glycol monolaurate and the non-ionic hydrophilic surfactant is polysorbate 80.

11~~12~~. A method for preparing a pharmaceutical preparation according to any one of claims 1 to 10~~11~~, comprising the following successive steps: dissolving the fexofenadine hydrochloride in a liquid mixture of at least one non-ionic hydrophilic surfactant and at least one non-ionic hydrophobic surfactant, with stirring, in order to obtain an homogeneous mixture; and then adjust the pH between 5-6 using suficient quantity of an acidifying or a basifying agent.

~~1012~~. The use of a composition as claimed in any one of claims 1 to ~~1011~~, for the preparation of a drug for the treatment of allergic reactions in a patient.